Effects of oral contraceptives on the quality of life of women with polycystic ovary syndrome: a crossover randomized controlled trial

Amiri, Mina; Nahidi, Fatemeh; Khalili, Davood; Tohidi, Maryam; Tehrani, Fahimeh Ramezani

doi:10.1186/s12955-020-01544-4

Cited by 10 publications

(9 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our research did not show any correlation between the use of OCPs and symptoms of depression. However, a previous study suggested that oral contraceptive pills are not indifferent to mental health [ 46 ]. Both positive and negative effects on psychiatric disorders have been reported among women using OCPs [ 47 ].…”

Section: Discussionmentioning

confidence: 99%

Depressive Symptoms and Control of Emotions among Polish Women with Polycystic Ovary Syndrome

Pokora

Kowalczyk

Wikarek

et al. 2022

IJERPH

View full text Add to dashboard Cite

Introduction: Polycystic ovary syndrome (PCOS) is a disorder that substantially affects women’s health. It is particularly diagnosed in young patients. Women with PCOS are burdened with excessive weight gain, overweight and obesity (74%) compared to a healthy female population. Excessive weight influences psychological state and emotional well-being, whereas in the meantime, psychological and behavioral dysfunction is increasingly being diagnosed among patients with PCOS. Aim: To assess depressive symptoms and emotional control among women with PCOS in relation to BMI. Methods: The study was conducted among 671 self-reported PCOS women. The standardized Beck Depression Inventory (BDI) was used to assess depressive disorders. Emotion control was assessed using the Courtauld Emotional Control Scale (CECS). Results: Moderate and severe depressive symptoms were more common in PCOS women with abnormal BMI compared to normal BMI subjects (p < 0.01). In total, 27.1% of obese women had moderate depression and 28.8% had severe depression. Among overweight women, 19.9% suffered from moderate and 25% from severe depressive symptoms. Underweight women also reported moderate (25.6%) and severe (33.3%) depressive signs. There were no statistically significant differences between the body weight of the women studied and the CECS scores. Conclusions: Depressive symptoms are more common in women with PCOS and abnormal BMI than in women with PCOS and proper BMI. The severity of depressive symptoms increases with BMI, but underweight women with PCOS are also at risk of depressive disorders. The level of suppression of negative emotions is independent of BMI in women with PCOS.

show abstract

Section: Discussionmentioning

confidence: 99%

Depressive Symptoms and Control of Emotions among Polish Women with Polycystic Ovary Syndrome

Pokora

Kowalczyk

Wikarek

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…Nine studies compared oral contraceptives containing drospirenone (DRSP) with the second-generation progestin, levonorgestrel (LNG). [29][30][31][32][33][34][35][36][37] Eight studies evaluated dienogest (DNG)-containing COCs, 29,30,[38][39][40][41][42][43] and one trial assessed nomegestrol acetate (NOMAC). 44 Two studies compared cyproterone acetate (CPA)-containing COCs against other generation progestins.…”

Section: Study Selection and Characteristicsmentioning

confidence: 99%

Harms of third- and fourth-generation combined oral contraceptives in premenopausal women: A systematic review and meta-analysis

Flores-Rodríguez

González-Colmenero

García-Leal

et al. 2023

Journal of Investigative Medicine

View full text Add to dashboard Cite

We assessed the available evidence regarding adverse effects on surrogate and patient-important health outcomes of third- and fourth-generation combined oral contraceptives among premenopausal women. We performed a systematic review and meta-analysis including randomized controlled trials and observational studies comparing third- and fourth-generation combined oral contraceptives with other generation contraceptives or placebo. Studies that enrolled women aged 15 to 50 years, with at least three cycles of intervention and 6 months of follow-up were included. A total of 33 studies comprising 629,783 women were included. Low-density lipoprotein cholesterol levels were significantly lower in fourth-generation oral contraceptives (mean differences (MD): −0.24 mmol/L; [95% CI −0.39 to −0.08]), while total cholesterol was significantly increased in levonorgestrel users when compared to third-generation oral contraceptives (MD: 0.27 mmol/L; [95% CI 0.04 to 0.50]). A decreased arterial thrombosis incidence was shown in fourth-generation oral contraceptive users, as compared to levonorgestrel (incidence rate ratio (IRR): 0.41; [95% CI 0.19 to 0.86]). No difference was found in the occurrence of deep venous thrombosis between fourth-generation oral contraceptives and levonorgestrel users (IRR: 0.91; [95% CI 0.66 to 1.27]; p = 0.60; I2 = 0%). Regarding the remaining outcomes, data were heterogeneous and showed no clear difference. In premenopausal women, the use of third- and fourth-generation oral contraceptives is associated with an improved lipid profile and lower risk of arterial thrombosis. Data were inconclusive regarding the rest of outcomes assessed. This review was registered in PROSPERO with CRD42020211133.

show abstract

“…• Рекомендуется проводить терапию комбинированными гормональными контрацептивами (КГК): КОК (по АТХ -Прогестагены и эстрогены (фиксированные сочетания)), пластырь, интравагинальное кольцо у пациенток с СПЯ, нарушениями менструального цикла и клиническими проявлениями гиперандрогении (гирсутизм и акне) в качестве терапии первой линии [59][60][61][62][63][64].…”

Section: уур -а (удд -1)unclassified

Clinical guidelines «Polycystic Ovary Syndrome»

Adamyan

Андреева

Absatarova

et al. 2022

Probl Endokrinol (Mosk)

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is a polygenic endocrine disorder caused by both genetic and epigenetic factors. Depending on the period of a woman’s life, the clinical picture, diagnosis, and treatment tactics of the disease are different. PCOS has a complex of reproductive, metabolic and psychological characteristics. The target audience of these clinical recommendations are obstetrician-gynecologists, endocrinologists, general practitioners, general practitioners. In these clinical guidelines, all information is ranked according to the level of persuasiveness of recommendations and the reliability of evidence, depending on the number and quality of studies on this issue.

show abstract

Effects of oral contraceptives on the quality of life of women with polycystic ovary syndrome: a crossover randomized controlled trial

Cited by 10 publications

References 50 publications

Depressive Symptoms and Control of Emotions among Polish Women with Polycystic Ovary Syndrome

Depressive Symptoms and Control of Emotions among Polish Women with Polycystic Ovary Syndrome

Harms of third- and fourth-generation combined oral contraceptives in premenopausal women: A systematic review and meta-analysis

Clinical guidelines «Polycystic Ovary Syndrome»

Contact Info

Product

Resources

About